PURA - Puration 2018 Sales Exceed $1 Million Goal With 2019 Goal Set At $5 Million and NOUV Dividend Coming Sooner Than Planned
December 20 2018 - 11:28AM
InvestorsHub NewsWire
PURA - Puration 2018 Sales Exceed
$1 Million Goal With 2019 Goal Set At $5 Million and NOUV Dividend
Coming Sooner Than Planned
Dallas, TX -- December 20, 2018 --
InvestorsHub NewsWire -- Puration, Inc. (USOTC:
PURA) (“PURA”) today released an online shareholder update that
includes details on the company’s progress toward 2018 sales goals
and an outlook on 2019 sales. The update also includes new
information on previously announced plans to issue a dividend of
Nouveau Life Pharmaceuticals, (USOTC:
NOUV) (“NOUV”) stock to PURA shareholders that will speed up
the issuance in addition to, management believes, improving the
overall value of the dividend. Management also includes in
the update highlights of business developments with US Cannabis
Health partners NOUV and Kali-Extracts (USOTC:
KALY). The narrative of the update can be found below in
addition to finding the full update on the company’s website at
www.purationinc.com.
2018 $1 Million Sales
Goal
Driven primarily by the growing market
penetration of our first cannabis sector beverage, EVERx CBD Sports
Water, PURA has well exceeded its $1 million 2018 sales goal.
In addition to throughput increasing within existing channels,
EVERx is now enjoying regional expansion. PURA has recently
announced new distributors in new areas around the U.S., and
anticipates soon announcing its first international distribution
agreements.
The recent addition of Telluride Happy
Water to the PURA product line has also contributed to sales
growth. PURA just announced a 100-pallet order that included
a strategic marketing campaign in partnership with the Austin,
Texas based distributor. We met this week to plan the
marketing campaign and we are very excited to roll the program out
starting in January.
The recent $1 million agreement with
Generex Biotechnology, Corp. (OTCQB) to produce private label CBD
infused water is a major contribution to 2019 sales. We
reasonably believe we can anticipate our current channels to at
least produce the same $1 million in sales in 2019 that came from
those channels this year. Now add to that the Generex $1
million agreement and we are already on track to double sales in
2019. However, we except our existing channels to expand
sales and we are on track with establishing new channels. So,
we are optimistic that $3 million in sales next year is a
reasonable goal and we’re even setting a stretch goal of $5 million
in sales with the additional sales contributions anticipated from
our other beverage lines to include Telluride Happy Water and
THCSavor.
Upcoming Dividend
Distribution
PURA recently spun-off its cannabis
cultivation operation with facilities in the U.S. and Canada to
NOUV. In conjunction with the spin-off, a portion of the
consideration that PURA received from NOUV was slated to be
converted into common stock and that NOUV common stock was to be
issued to shareholders of PURA. Specifically, PURA sold its
cannabis cultivation business to NOUV in exchange for a $1.2
million convertible note with a commitment that the note would
promptly be converted to common shares of NOUV and that those
converted shares would be distributed in a stock dividend to the
shareholders of PURA. PURA and NOUV originally planned to
wait for NOUV to execute a reverse spilt before executing the
dividend distribution. While pursuing that objective, it
became clear the execution of the reverse split would take some
time. As NOUV updates its filings and executes on its
business plan with the new cannabis cultivation operation,
optimistically, a reverse split of NOUV might not be
necessary. So, PURA and NOUV management have explored
alternative options. In light of the fact that the common
shares of NOUV issued to PURA shareholders will not be immediately
free trading and will have to season to be free trading under an
exemption from registration, PURA and NOUV have resolved to issue a
dividend of preferred shares convertible into common shares.
In this way, a dividend of equity can be rapidly issued and the
seasoning of shares for exemption can begin. If a NOUV
reverse proceeds as originally planned, then shareholders will
receive the original allocation of 1 common share for every 5
shares of PURA. If a reverse proves unnecessary, then the
conversion of preferred shares into common shares will be adjusted
accordingly to affect an equal dividend
allocation.
US Cannabis Health Joint
Venture
The Joint Venture (JV) partnership with
KALY and NOUV is proceeding even better than anticipated.
KALY and NOUV today announced an agreement to expand NOUV’s current
cultivation operations to include 100 adjacent acers dedicated to
growing hemp under the new Farm Bill legalizing hemp farming and
anticipated to be signed into law later today by President
Trump. KALY will construct a CBD extraction facility on site
based on KALY’s patented extraction process. In addition to
the outdoor hemp cultivation, NOUV will build a state-of-the-art
greenhouse operation intended for the development of a proprietary
hemp cultivar.
Now that KALY’s filings are cleaned up
with OTCMarkets and Frederick Ferri has taken the reins and CEO,
the caliber of KALY’s assets and capabilities is becoming more
clear to the market. KALY produces pharmaceutical grade
cannabis extracts that have been involved in multiple clinical
trials in addition to utilizing its patented cannabis extraction
process in the production of CBD infused nutrition and wellness
products to include its own Hemp4mula and CBD infused waters
produced by PURA.
As PURA shareholders likely know, NOUV has
a cannabis cultivation operation with facilities in the U.S. and
Canada. NOUV’s objective in the partnership announced today
with KALY is to develop a proprietary pharmaceutical grade hemp
cultivar in addition to being a source of hemp supply for a myriad
of industries in what management anticipates to be exploding demand
in 2019.
KALY, NOUV and PURA are partners in US
Cannabis Health for the purpose of together developing partnerships
with pharmaceutical companies to develop cannabis
pharmaceuticals. US Cannabis Health recently announced its
first agreement with Generex Biotechnology, Corp. (OTCQB:
GNBT).
To learn more
about Puration, Inc., visit www.purationinc.com
To learn more
about Kali-Extracts, Inc., visit www.kali-extracts.com
Disclaimer/Safe
Harbor:
This
news release contains forward-looking statements within the meaning
of the Securities Litigation Reform Act. The statements reflect the
Company's current views with respect to future events that involve
risks and uncertainties. Among others, these risks include the
expectation that any of the companies mentioned herein will achieve
significant sales, the failure to meet schedule or performance
requirements of the companies' contracts, the companies' liquidity
position, the companies' ability to obtain new contracts, the
emergence of competitors with greater financial resources and the
impact of competitive pricing. In the light of these uncertainties,
the forward-looking events referred to in this release might not
occur. These statements have not been evaluated by the Food and
Drug Administration. These products are not intended to diagnose,
treat, cure, or prevent any disease.
Puration, Inc.
Brian Shibley,
info@aciconglomerated.com
(800) 861-1350
Nouveau Life Pharmaceuti... (PK) (USOTC:NOUV)
Historical Stock Chart
From Mar 2024 to Apr 2024
Nouveau Life Pharmaceuti... (PK) (USOTC:NOUV)
Historical Stock Chart
From Apr 2023 to Apr 2024